Net Profit Margin: 9.12%
Is the net profit margin high or low?
The net profit margin of 9.12% is 24% above its 5-year average of 7.35%, around the middle of its 5-year range (0.35%–20.19%).
As of Friday, June 26, 2026. 37.77% below its 12-month average of 14.66%.
PODD Profit Margin Chart
Annual fiscal-year profit margin; no daily interpolation.
PODD Average Net Profit Margin Chart
PODD Current vs Average Net Profit Margin Chart
PODD Net Profit Margin Metrics
NET PROFIT MARGIN
9.12%
NET PROFIT MARGIN AVG TTM
14.66%
NET PROFIT MARGIN AVG 3Y
10.46%
NET PROFIT MARGIN AVG 5Y
7.35%
NET PROFIT MARGIN AVG 10Y
0.43%
NET PROFIT MARGIN AVG 15Y
-6.23%
NET PROFIT MARGIN AVG 20Y
-16.29%
CURRENT VS TTM AVG
-37.77%
CURRENT VS 3Y AVG
-12.77%
CURRENT VS 5Y AVG
+24.08%
CURRENT VS 10Y AVG
+2020.93%
CURRENT VS 15Y AVG
+246.47%
CURRENT VS 20Y AVG
+155.99%
PODD Competitors' Net Profit Margin
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Insulet Corp. (PODD) | $11.07B | 9.12% | 14.66% | 10.46% | 7.35% |
| Baxter International Inc. (BAX)vs › | $11.42B | -9.70% | -7.30% | -3.29% | 1.14% |
| Molina Healthcare, Inc. (MOH)vs › | $11.63B | 0.42% | 1.97% | 2.41% | 2.58% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -4.07% | -4.03% | -0.72% | 0.14% |
| Charles River Laboratories International, Inc. (CRL)vs › | $10.17B | -4.59% | -1.67% | 5.09% | 7.31% |
| Henry Schein, Inc. (HSIC)vs › | $9.61B | 2.95% | 3.05% | 3.43% | 3.79% |
| Revvity, Inc. (RVTY)vs › | $12.56B | 8.30% | 9.60% | 8.02% | 12.66% |
| DaVita Inc. (DVA)vs › | $13.72B | 5.65% | 6.39% | 5.83% | 6.41% |
| Solventum Corporation (SOLV)vs › | $13.75B | 17.33% | 12.25% | 14.36% | 15.15% |
| The Cooper Companies, Inc. (COO)vs › | $14.00B | 5.57% | 9.62% | 9.77% | 24.94% |
Margin Comparison
Operating Margin
17.5%
Net Profit Margin
9.1%
Net Profit Margin Formula & Definition
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Net Profit Margin FAQ
- What is the net profit margin for Insulet Corp. (PODD)?
- The net profit margin for PODD stock is 9.12%.
- Is Insulet Corp.'s net profit margin high or low?
- The net profit margin of 9.12% is 24% above its 5-year average of 7.35%, around the middle of its 5-year range (0.35%–20.19%).
- What is the TTM average net profit margin for Insulet Corp. (PODD)?
- The TTM average net profit margin for PODD stock is 14.66%.
- What is the 3Y average net profit margin for Insulet Corp. (PODD)?
- The 3Y average net profit margin for PODD stock is 10.46%.
- What is the 5Y average net profit margin for Insulet Corp. (PODD)?
- The 5Y average net profit margin for PODD stock is 7.35%.
- What is the 10Y average net profit margin for Insulet Corp. (PODD)?
- The 10Y average net profit margin for PODD stock is 0.43%.
- What is the 15Y average net profit margin for Insulet Corp. (PODD)?
- The 15Y average net profit margin for PODD stock is -6.23%.
- What is the 20Y average net profit margin for Insulet Corp. (PODD)?
- The 20Y average net profit margin for PODD stock is -16.29%.
PODD Net Profit Margin History
| DATE | NET PROFIT MARGIN |
|---|---|
| 2025-12-31 | 9.12% |
| 2024-12-31 | 20.19% |
| 2023-12-31 | 12.16% |
| 2022-12-31 | 0.35% |
| 2021-12-31 | 1.53% |
| 2020-12-31 | 0.75% |
| 2019-12-31 | 1.57% |
| 2018-12-31 | 0.58% |
| 2017-12-31 | -5.79% |
| 2016-12-31 | -7.87% |
| 2015-12-31 | -27.86% |
| 2014-12-31 | -17.84% |
| 2013-12-31 | -18.20% |
| 2012-12-31 | -24.54% |
| 2011-12-31 | -37.55% |
| 2010-12-31 | -63.07% |
| 2009-12-31 | -120.46% |
| 2008-12-31 | -257.33% |
| 2007-12-31 | -400.38% |
| 2006-12-31 | -981.44% |
| 2005-12-31 | -43272.00% |
| 2004-12-31 | 0.00% |
| 2003-12-31 | 0.00% |
| 2002-12-31 | 0.00% |
Related Metrics
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy